Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
322
resultados
Última actualización
25/08/2026 [07:57:00]
Resultados 300 a 322 de 322
Resumen de: WO2025146757A1
This method for quantifying plasmalogens comprises: a measurement sample preparation step for mixing a Schiff reagent with a specimen containing protein and plasmalogens to obtain a measurement sample; a control sample preparation step for mixing the specimen with a solvent of the Schiff reagent to obtain a control sample; a measurement step for measuring the extent of a first optical property of the measurement sample, the first optical property being obtained by reacting the Schiff reagent with an aldehyde generated from vinyl ether bonds of the plasmalogens, and measuring the extent of the optical property of the control sample; and a determination step for determining the concentration of plasmalogens in the specimen by comparing the correction extent, that is the extent to which the extent of the first optical property has been corrected by the extent of the optical property of the control sample, with the extent of a second optical property of a standard sample containing the Schiff reagent and a known concentration of plasmalogens, the second optical property being the optical property after the Schiff reagent has been reacted with the aldehyde generated from the vinyl ether bonds of the plasmalogens.
Resumen de: CN122297687A
0001 本发明提供了乳酰化修饰PRDX5蛋白及其产品和应用，属于生物医药技术领域。本发明揭示了PRDX5 K71位点乳酰化修饰在COPD病理进程中的关键作用，其在COPD小鼠海马组织神经元乳酰化水平异常升高，且与小鼠认知功能障碍的发生发展密切相关；同时提供了靶向该位点的特异性干预方案，通过立体定位注射重组腺相关病毒PRDX5 K71R突变体降低或阻断K71位点发生乳酰化修饰的可能性，可有效改善COPD小鼠的学习记忆与空间定位能力，为认知功能障碍的机制研究与靶向防治提供了新的分子靶点和实验依据。
Resumen de: KR20260101594A
본원은 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다. 더욱 상세하게, 본원은 아밀로이드 베타와의 결합력 및 선택성 증가로 정확도가 개선된 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다.
Resumen de: KR20260100566A
본 발명은 알파-시누클레인 단백질에 특이적으로 결합하는 DNA 앱타머 및 이의 용도에 관한 것으로, 구체적으로 본 발명은 서열번호 1 내지 12의 염기서열로 이루어진 군 중에서 선택되는 알파-시누클레인(α-synuclein) 단백질에 특이적으로 결합하는 DNA 앱타머(aptamer), 상기 앱타머를 유효성분으로 포함하는 알파-시누클레인 단백질 검출용 조성물, 검출용 키트, 검출용 칩 또는 마이크로어레이에 관한 것이며, 또한 본 발명은 본 발명의 DNA 앱타머를 이용한 알파-시누클레인 단백질의 검출방법, 퇴행성 뇌질환의 진단을 위한 정보 제공 방법, 퇴행성 뇌질환의 진단용 조성물 및 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물에 관한 것이다.
Resumen de: CN122297477A
0001 本发明涉及生物医药领域，公开了一种含有2,4‑噻唑环的化合物在抗衰老中的应用。含有2,4‑噻唑环的化合物为式X所示化合物或其药学上可接受的盐，其中式X化合物包括具有吡唑并嘧啶骨架的式I类化合物和具有吲哚骨架的式II类化合物。本发明人首次发现IL4I1是调控细胞衰老的关键分子，并阐明了式X化合物通过靶向IL4I1，解除IL4I1对EIF4B的泛素化降解，上调EIF4B‑PGAM5轴表达，从而维持线粒体稳态、延缓细胞及组织衰老的作用机制。实验结果表明，本发明所述含有2,4‑噻唑环的化合物可有效预防放化疗诱导的细胞衰老，减轻放疗诱导的小鼠整体衰老，改善运动功能，降低衰老相关分泌表型因子分泌，缓解器官纤维化。本发明为开发新型抗衰老药物提供了新的化学分子基础和作用靶点。
Resumen de: WO2026145099A1
Provided in the present invention is the use of NUCB1 in the prevention and/or treatment of autoimmune diseases. Specifically provided in the present invention is the use of an NUCB1 gene, or a protein thereof, or a promoter thereof in the preparation of a composition or preparation, wherein the composition or preparation is used for preventing and/or treating autoimmune diseases. The NUCB1 gene, or the protein thereof, or the promoter thereof of the present invention can significantly prevent and/or treat autoimmune diseases, and is particularly effective against systemic lupus erythematosus, atopic dermatitis, rheumatoid arthritis, psoriasis, multiple sclerosis, or Crohn's disease.
Resumen de: CN122307115A
本发明提供一种生物标志物在制备轻度认知障碍风险评估产品中的用途，所述生物标志物包括Aβ寡聚体。单独的Aβ寡聚体标志物对MCI具有显著的预测价值，在区分认知正常与MCI的受试者时，其测试集受试者工作特征曲线下面积（AUC）即可达到 0.851（95% 置信区间:0.803 ‑ 0.895），证明其在区分出MCI受试者具有优越的性能。
Resumen de: US12668835B1
A sample holder includes a first member featuring a first retaining mechanism configured to retain a first substrate that includes a sample, a second member featuring a second retaining mechanism configured to retain a second substrate that includes a reagent medium, and an alignment mechanism connected to at least one of the first and second members, and configured to align the first and second members such that the sample contacts at least a portion of the reagent medium when the first and second members are aligned.
Resumen de: KR20260099247A
본 발명은 파킨슨병 및 시누클레인병증 진단을 위한 키트 및 검출 방법에 관한 것이다. 본 발명의 키트 및 검출 방법을 이용하면 환자의 혈장을 이용하여 비침습적이면서도 높은 정확도를 가지고 파킨슨병과 시누클레인병증을 진단할 수 있다.
Resumen de: WO2026134051A1
This plasmalogen detection method comprises: a sample preparation step for mixing a Schiff's reagent and a specimen containing a plasmalogen to obtain a sample; a reaction step for reacting the plasmalogen in the sample with the Schiff's reagent; and a contact step for bringing at least some of the sample reacted in the reaction step into contact with a stationary phase containing a silica gel.
Resumen de: CN122283146A
0001 本发明提供了人源卵泡抑素样蛋白（FSTL1）作为特发性正常压力脑积水标记物的应用及检测方法及试剂盒，其中，人源卵泡抑素样蛋白（FSTL1）的NCBI Gene ID 11167，RefSeq mRNA编号为NM_007085.5，RefSeq蛋白编码为NP_009016.1，UniProt编号为Q12841。本发明解决了现有检测技术中存在的无法早期分子识别、标志物特异性不足、低丰度蛋白检测灵敏度不足的技术问题。
Resumen de: CN122277725A
本申请实施例提供了一种抗NFL蛋白的单克隆抗体组合及其用途。所述单克隆抗体组合包括第一抗体和第二抗体，第一抗体包括第一重链可变区和第一轻链可变区，第二抗体包括第二重链可变区和第二轻链可变区；第一重链可变区包括如SEQ ID NO:3‑5所示的三个互补决定区，第一轻链可变区包括如SEQ ID NO:6‑8所示的三个互补决定区；第二重链可变区包括如SEQ ID NO:11‑13所示的三个互补决定区；第二轻链可变区包括如SEQ ID NO:14‑16所示的三个互补决定区。本实施例提供的单克隆抗体组合具有优异的特异性和高亲和力，可用于体外定量检测血清中NFL浓度，为神经系统相关疾病的辅助诊断提供技术支持。
Resumen de: CN122277723A
0001 本发明公开了检测载脂蛋白E4的抗体及其应用，具体涉及检测阿尔茨海默症血液标志物ApoE4的检测抗体和试剂盒，基于该抗体及试剂盒能够准确的检测载脂蛋白E4的存在。
Resumen de: CN122282992A
本发明提供了一种测定人血浆中β‑淀粉样蛋白42/40比率的质谱方法，包括采用¹5N稳定同位素标记的完整Aβ42和Aβ40蛋白作为内标，通过免疫沉淀技术对血浆样本进行提取与纯化，并利用Lys‑N蛋白酶解产生特征性肽段，最终通过液相色谱‑串联质谱进行靶向定量分析。Aβ42的特征肽段是Aβ28‑42 KGAIIGLMVGGVVIA；Aβ40的特征肽段是Aβ28‑40 KGAIIGLMVGGVV。相较于完整蛋白，本发明中的特征肽段不易发生聚集且在质谱中具有更高的电离效率，展现出优异的特异性、重复性与灵敏度，能够为阿尔茨海默症的诊断提供可靠依据。
Resumen de: CN122283145A
本发明属于检测技术领域，本发明具体公开了一种磷酸化Tau181蛋白测定试剂盒及应用，本申请所述的抗试剂A和抗试剂B中的p‑Tau181抗体中的生物素和碱性磷酸酶发生反应，形成抗体‑抗原‑抗体复合物并通过生物素与链霉亲和素的反应结合到磁性微粒上，加入化学发光底物AMPPD，碱性磷酸酶催化AMPPD产生化学发光信号，通过光学检测系统测量发光强度，仪器自动通过工作曲线计算得出检测结果，本申请通过对试剂盒的抗试剂A和抗试剂B以及磁微粒试剂进行设计，能够精准捕获抗体并放大信号，有效的降低检测限，提升试剂盒的综合性能。
Resumen de: CN122283142A
本发明公开了一种用于阿尔茨海默病早期筛查的泪液检测装置及方法，属于体外诊断医疗器械技术领域，包括泪液采样器、微流控芯片和便携式读数器，泪液采样器用于将采集并预处理的泪液样本输送至微流控芯片，微流控芯片上设置有样品输入口，泪液采样器与样品输入口连接，微流控芯片上设置有用于检测生物标志物的微通道结构，且微流控芯片能置于便携式读数器的卡槽内，便携式读数器用于进行信号检测并对监测数据进行分析后输出诊断结果。本发明采用上述的一种用于阿尔茨海默病早期筛查的泪液检测装置及方法，旨在实现阿尔茨海默病的早期、快速、高灵敏度诊断。
Resumen de: CN122283112A
The invention provides a sample analysis device, a sample analysis system, a sample analysis method, and a program, which contribute to high-accuracy cognitive disease diagnosis using a cognitive disease biomarker. A sample analysis device (1) is provided with: a measurement device (2) that measures an analyte that is included in a sample collected from a subject and that relates to a biomarker of a cognitive disorder; a storage unit that stores a reference value for specifying an outlier that can be generated on the basis of factors other than the cognitive disorder; a control unit that, on the basis of a measurement value of the analyte provided by the measurement device (2) and a reference value, determines whether or not to determine the measurement value as an outlier, and generates an analysis result of the biomarker on the basis of the result of the determination; and an output unit that outputs the analysis result of the biomarker.
Resumen de: CN122291031A
0001 本发明公开了一种基于不良结局路径模型的污染物联合暴露毒性风险预警方法，建立联合暴露体系，将受试对象分为空白对照组、单一污染物暴露组及联合暴露组，在预设环境条件下进行暴露；在暴露过程中设置两个采样时间点，包括第一采样时间点和第二采样时间点；获取受试对象多层级检测指标数据，包括生化指标、组织病理指标、表面超微结构指标和/或基因表达指标；基于所述多层级检测指标数据，识别不良结局路径中的分子起始事件、早期关键事件、后期关键事件及不良结局，建立分子起始事件至关键事件再至不良结局的因果关联链条；根据不良结局的出现情况，输出分级风险预警结果。联合暴露体系中的受试对象为鱼类，污染物为全氟辛酸和聚苯乙烯微塑料。
Resumen de: AU2024312747A1
The present disclosure relates method of identifying a compound targeting a first protein and a second protein, wherein the first protein and/or the second protein are associated with a disease or disorder.
Resumen de: CN122283116A
本发明公开了一种神经轻链蛋白的检测试剂盒、方法及磁性水凝胶制备方法，本发明的检测试剂盒，包含磁性水凝胶偶联探针，神经轻链蛋白检测抗体，预激发液和激发液；其中，磁性水凝胶偶联探针为表面络合有顺磁性的纳米四氧化三铁粒子的含羧基聚合物球形颗粒。
Resumen de: EP4560314A1
0001 The present invention relates to an ex vivo method for mapping the spatiotemporal electrophysiological dynamics and spatial transcriptional profiles of cells in a functional neuronal cell assembly, comprising simultaneous recording and analysis of spatial data of molecular and electrical network activity down to the level of individual cells using high-density electrical biosensors, spatial transcriptomics, optical imaging, and advanced computational strategies. The invention further relates to methods for identifying the composition of a functional neuronal assembly, for monitoring the spatiotemporal electrophysiological dynamics and transcriptional profiles of cells in a functional neuronal cell assembly, for monitoring the cellular composition of a functional neuronal assembly, or for identifying a compound having an effect on the spatial electrophysiological and transcriptional dynamics and/or for identifying the composition of cells in a functional neuronal cell assembly based on the dynamics as detected, as well as devices and uses thereof. The invention allows for a better understanding of disease mechanisms, and to find therapeutic targets and to develop new drugs and treatments.
Nº publicación: CN122295354A 26/06/2026
Solicitante:
欧萨尔普罗席纳有限公司
Resumen de: WO2025059487A2
The present disclosure provides cell penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human beta amyloid and methods of using these cell penetrating agents to treat patients with beta amyloid related diseases, including Inclusion-body myositis (IBM).
BOPI
Sede Electrónica
